ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MTPH Midatech Pharma Plc

18.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma Plc LSE:MTPH London Ordinary Share GB00BNGF1L75 ORD GBP0.02
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 18.00 17.00 19.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Midatech Pharma Share Discussion Threads

Showing 401 to 425 of 2250 messages
Chat Pages: Latest  18  17  16  15  14  13  12  11  10  9  8  7  Older
DateSubjectAuthorDiscuss
10/1/2019
15:14
Rake -

Looks like NOBBY is correct -

Nobbygnome10 Jan '19 - 13:13 - 233 of 238
0 2 0
tomboy

I think you are wrong in your comparison of prices. One ADS is equivalent to 2 shares on AIM so the price should be around 8p based on the US price.

tomboyb
10/1/2019
14:37
Current price is 0.20c which equates to around 16 pence
rakepat37
10/1/2019
14:27
Lets see what the market over at U.S makes of the news today -

Selling at 6.75p when the market across the pond is around 8pish mark -

Will look to add further on any weakness -

tomboyb
10/1/2019
13:52
Check out the 5 dollers price target
rakepat37
10/1/2019
13:38
yes I see now. thanks.
babbler
10/1/2019
13:19
Nobby -

Thanks -

If u see my previous posts i was asking the question of that discrepancy -

We are still below that share price (which is why i said i could not understand it and went in blindly at 6.25p) -

tomboyb
10/1/2019
13:13
tomboy

I think you are wrong in your comparison of prices. One ADS is equivalent to 2 shares on AIM so the price should be around 8p based on the US price.

nobbygnome
10/1/2019
12:36
Check out @portefeuillefun's Tweet: https://twitter.com/portefeuillefun/status/1083340718691762177?s=09
aba978731dom
10/1/2019
12:34
Back into ths 8p range here -

Discrepancy is massive -

It should certainly not be so -

Which begs the question of MARKET MAKERS and arbitrage -

tomboyb
10/1/2019
12:33
And now fully funded ... time to catch up to 16p
rakepat37
10/1/2019
12:20
convert it from dollars to GBP. What does the price equate to? Either a massive fall there or we need to catch up.
babbler
10/1/2019
12:14
Look at the price it's worth 16p
rakepat37
10/1/2019
12:07
What am i missing here. When I look at the nasdaq chart it shows 16% rise not the 100% people are talking about....
pilkersa
10/1/2019
12:03
Well I bought on the shake. us open soon...
babbler
10/1/2019
11:30
Idiotic punters are helping the MMs out by bailing out. Make their pips squeak!
nobbygnome
10/1/2019
10:49
OT) Please look at Futura Medical (FUM) has a dirt low market cap of 22 Million and 3 Drugs including a potential MEGA Blockbuster in Phase 3 trial which is light years better than Viarga and Cialis . If you look for a potential 10+ Bagger then load up FUM


Research Confirms MED2002's US$1 Billion Potential
hxxps://futuramedical.com/content/news/archive17/060317b.asp

The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time.

Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide.

Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life.

The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development.

The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action.

The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts.


Pipeline
hxxps://www.futuramedical.com/media/144144/Pipeline-2018.jpg

MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedical.com/content/products/med_2002.asp

first patient dosed: in Q3/Q4 2018
Last patient dosed: by end of June 2019
Headline efficacy results: by end of December 2019

CSD500: Erectogenic condom
hxxps://futuramedical.com/content/products/csd_500.asp

Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets.

Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedical.com/content/products/tpr_100.asp

TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018.
Out-licensing discussions for TPR100 outside of the UK are ongoing.

bioking
10/1/2019
10:49
array of 6.25p buyers did well there..well done folks.
pre
10/1/2019
10:47
Market makers in massive trouble here.... they desperately need some sellers but none appearing and unlikely to do so!
nobbygnome
10/1/2019
10:33
Will be up 80-100% at this rate today -
tomboyb
10/1/2019
10:22
Never seen that price discrepancy before and does not make sense -

However i've taken a blind punt at 6.25p -

tomboyb
10/1/2019
10:22
Can't believe people have not caught on that the USA market hit 16p last night -- wow this is going to go nuts
rakepat37
10/1/2019
10:20
Another 10p to go to get to 16p and then evens with USA, USA market opens soon then another uplift
rakepat37
10/1/2019
10:03
Correct me if i'm wrong but that looks like 15-16p?

V

6.5p here -

Views anyone? -

tomboyb
10/1/2019
10:02
To me this looks like going 7p+ pretty soon -

hxxp://www.midatechpharma.com/share-price-information

NASDAQ value -

tomboyb
10/1/2019
09:42
Took a few today -

Any ideas why the huge discrepancy - ( Blind punt)

tomboyb
Chat Pages: Latest  18  17  16  15  14  13  12  11  10  9  8  7  Older

Your Recent History

Delayed Upgrade Clock